Stryker Corp. continues to experience issues with its LFIT Anatomic CoCr V40 Femoral Head, a hip replacement component that was the subject of a 2016 recall.
Stryker’s LFIT V40 femoral heads are designed to be used in conjunction with many of the company’s modular hip stems, including:
In August 2016, Stryker announced a worldwide recall for certain LFIT Anatomic CoCr V40 Femoral Heads manufactured prior to 2011, after the devices were associated with an unusually high rates of taper lock failure. Complications related to taper lock failure may include:
The Stryker hip recall was given Class II designation by the U.S. Food & Drug Administration (FDA), which indicates that the affected components could cause temporary or medically-reversible health consequences.
Late last month, Stryker warned that certain LFIT V40 Femoral heads had been associated with a higher-than-usual number of complaints involving femoral head/hip stem disassociation.
Such an occurrence can result in serious complications, including:
Stryker has not asked healthcare providers to return any of the affected LFIT V40 Femoral Heads, which were manufactured between 2001 and May 2011, as they would have already been implanted in patients or expired. The company has advised surgeons to continue normal follow-up with the recipients of these components.
Thousands of plaintiffs have filed Stryker hip lawsuits that seek compensation for injuries and complications associated with LFIT V40 Femoral Heads affected by the 2016 recall.
These cases include more than 3,100 that have been consolidated in a multidistrict litigation now underway in the U.S. District Court, District of Massachusetts. Hundreds of additional Stryker hip lawsuits involving LFIT V40 Femoral Heads have been centralized in New Jersey’s Bergen County Superior Court.